Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs JD, MPH, discusses the recent Inflation Reduction Act that will ultimately enable Medicare to negotiate drug prices with the pharmaceutical industry.
Tag: Rachel Sachs
Since Biden took over, Big Pharma has spent $205 million to protect drug price status quo, analysis finds (Links to an external site)
Rachel Sachs JD, MPH, institute Faculty Scholar and Treiman Professor of Law at the School of Law, speaks with Fierce Pharma about the pharmaceutical industry’s response to the Biden administration, specifically the recent Inflation Reduction Act.
How Medicare drug costs could change under the Inflation Reduction Act (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs JD, MPH, discusses the impact of a new bill that allows Medicare to negotiate drug prices for a select number of expensive drugs.
HEALTH CARE BRIEFING: Drug Bill Shows Limits of Democrat’s Power (Links to an external site)
Rachel Sachs JD, MPH, institute faculty scholar and Treiman Professor of Law at the School of Law, discusses recent federal legislation that enables Medicare to negotiate the prices of some of the most expensive pharmaceuticals
Major drug price reforms head for Biden’s signature as PhRMA weighs legal options (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law at the School of Law, Rachel Sachs JD, MPH, discusses with EndpointNews possible legal avenues for PhRMA following recent federal legislation
Dems’ Medicare win faces long, uncertain future (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs discusses the new bill that would allow Medicare to negotiate drug prices for a select number of expensive drugs.
Drug industry on verge of rare defeat (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs discusses the new bill that would allow Medicare to negotiate drug prices for a select number of expensive drugs
Drug industry poised for rare political loss on prices (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs discusses the new Senate bill that would allow Medicare to negotiate drug prices for a select number of very expensive drugs in this Washington Post article.
Ad Targeting Manchin and AARP Mischaracterizes Medicare Drug-Price Negotiations (Links to an external site)
Institute Faculty Scholar and Treiman Professor of Law, Rachel Sachs, weighs in on the validity of an ad targeting Senator Joe Manchin and AARP, characterizing it as “fairly misleading”
People with chronic illness in US now having medication restricted (Links to an external site)
Rachel Sachs, institute faculty scholar and Treiman Professor of Law at the School of Law, discusses with Bloomberg the potential for restrictions on medications in Missouri following the Supreme Court’s overturning of Roe v. Wade.